中国医院科学院阜外医院陈亮教授团队最近发表的一项大规模人群基础研究[3]显示,在中国的低风险和一级预防人群中,LDL-C与全因死亡和心血管疾病(CVD)死亡存在U型关系,表明LDL-C水平过低或过高都可能增加心血管病风险。在二级预防中,LDL-C...
相对于LDL-C降幅≥50%组,降幅<50%组患者基线LDL-C水平较低(97.7±32.3 vs. 138±36.7 mg/dL,P<0.001)(表1),相反,随访12个月后,降幅<50%组患者LDL-C水平更高(81.5±27.0 vs. 53.5±14.8 mg/dL,P<0.001)(表2),而胆...
However, the current analyses may slightly underestimate goal attainment with these treatments in the high-risk population. Entry criteria in the trials required patients to have LDL-C levels ≥ 130 mg/dL,[8,9] requiring a ≥ 30 mg/dL reduction to reach the LDL-C goal of 100 mg/dL and ...
ANMCO (Associazione Nazionale Medici Cardiologi Ospedalieri) presenta la nuova app LDL-C GOAL, uno strumento agile e immediato per individuare il trattamento pi…
ANMCO (Associazione Nazionale Medici Cardiologi Ospedalieri) presenta la nuova app LDL-C GOAL, uno strumento agile e immediato per individuare il trattamento pi…
Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia. Int J Clin Pract. 2006;60:914-21. [PMID: 16893434]...
从VICTORION-INITIATE 研究来看,「优先联合英克司兰」治疗策略不仅可以长期强效平稳降低 ASCVD 患者血脂水平,提高血脂达标率;而且对于 ACS 后处于前 3 个月易损期的患者来说,英克司兰在首次注射后三个月 LDL-C 降幅即可达 57.7%,可为易损期患者提供稳定血脂保护,有效降低了这一易损期内因血脂波动导致的心血管事...
An important goal for people with atherosclerotic cardiovascular disease (ASCVD) is how to manage LDL-C (low-density lipoprotein-cholesterol).Aggressive LDL-C management is essential to prevent cardiovascular events and death. However, many people still
In the ODYSSEY ALTERNATIVE trial, alirocumab produced greater LDL-C reduction compared with ezetimibe in patients intolerant to statins (45% and 14.6% at week 24, respectively), and a higher percentage of patients reached the recommended LDL-C goal (41.9% vs 4.4%, respectively) (Moriarty et ...
LDL-C是糖尿病大血管并发症防治的首要目标 LDL-C是糖尿病大血管并发症防治的 首要目标中南大学湘雅二医院赵水平内容糖尿病属心血管疾 病冠心病等危症LDL-C是糖尿病降脂治疗的首要目标降低LDL-C 显著减少心血管事件发2型糖尿病80%死于糖尿病者有动脉粥